Silence Therapeutics plc

Transaction in Own Shares • Dec 17, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2140X

Silence Therapeutics PLC

17 December 2019

Management Change

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that CEO, David Horn Solomon, has today resigned.

Executive Chairman, Iain Ross, will lead the Company with immediate effect and commence a search to find a suitable successor. An update will be made to the market in due course.

Iain Ross, Executive Chairman of Silence Therapeutics, said: "We thank David for his contribution to Silence and wish him well for the future. The Company is in its most robust health both financially and operationally and we look forward to further BD discussions and scientific advancements with our pipeline."

Enquiries:

Silence Therapeutics plc Iain Ross, Chairman	Tel:  +44 (0)20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson	Tel:  +44 (0)20 7418 8900
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
US IR Westwicke Partners Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCZMMMZKNLGLZM